



Journal of the British Thoracic Society

Impact Factor: 9.655

**Editors-in-Chief**

N Hart (UK)  
G Jenkins (UK)  
AR Smyth (UK)

**Deputy Editor**

N Kaminski (USA)

**Associate Editors**

|                   |   |
|-------------------|---|
| D Baldwin (UK)    | J-L Pepin (France)                      |
| R Chambers (UK)   | M Polkey (UK)                           |
| T Coleman (UK)    | J Quint (UK)                            |
| GJ Criner (USA)   | N Rahman (UK)                           |
| J Davies (UK)     | K Robinson (USA)                        |
| A Floto (UK)      | S Seglani (UK)                          |
| M Griffiths (UK)  | R Stevens (USA)                         |
| L Heaney (UK)     | A Vonk Noordegraaf<br>(The Netherlands) |
| N Hopkinson (UK)  | C Wainwright (Australia)                |
| S Janes (UK)      | T Wilkinson (UK)                        |
| DL Jarvis (UK)    | P Wolters (USA)                         |
| B Kampman (UK)    |   |
| B Mohkelesi (USA) |   |

**Statistical Editors**

A Douiri (UK)  
C Flach (UK)  
C Jackson (UK)  
S Stanojevic (USA)  
R Szczesniak (USA)  
B Wagner (USA)  
Y Wang (UK)

**Journal Club Editor**

P Murphy (UK)

**Multimedia Editor**

R Moses (UK)

**President, British Thoracic Society**

Professor M Woodhead

**Editorial Office**

Thorax, BMJ Journals, BMA House,  
Tavistock Square, London, WC1H 9JR, UK  
T: +44 (0)20 7383 6373  
E: [thorax@bmj.com](mailto:thorax@bmj.com)

Twitter: @ThoraxBMJ

ISSN: 0040-6376 (print)

ISSN: 1468-3296 (online)

**Disclaimer:** Thorax is owned and published by the British Thoracic Society and BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association. The owners grant editorial freedom to the Editor of Thorax.

Thorax follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

Thorax is intended for medical professionals and is provided without warranty, express or implied. Statements in the Journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group Ltd, the British Thoracic Society or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group Ltd shall not be liable for any loss, injury or damage resulting from the use of Thorax or any information in it whether based on contract, tort or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2019 BMJ Publishing Group Ltd and the British Thoracic Society. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior permission of Thorax.

Thorax is published by BMJ Publishing Group Ltd, typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Thorax (ISSN No: 0040-6376) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to Thorax, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

**Guideline highlights**

- 1 Updated BTS Adult Bronchiectasis Guideline 2018: a multidisciplinary approach to comprehensive care  
*A T Hill, S A Welham, A L Sullivan, M R Loebinge*

**Editorials**

- 4 Emerging biology of persistent mucous cell hyperplasia in COPD  
*R Shaykhi*
- 7 Process evaluation and the development of behavioural interventions to improve psychological distress among survivors of critical illness  
*A M Parker, A Malik, M Hosey*
- 11 Socioeconomic deprivation and inequalities in lung cancer: time to delve deeper?  
*H A Powell*
- 13 Where next for cell-based therapy in ARDS  
*A J Boyle, C M O'Kane, D F McAuley*
- 16 Balancing fairness and efficacy in lung allocation for transplantation: unfinished business  
*K C Meyer*

**Chronic obstructive pulmonary disease**

- 18 NOTCH3 contributes to rhinovirus-induced goblet cell hyperplasia in COPD airway epithelial cells  
*Y Jing, J A Gimenes, R Mishra, D Pham, A T Comstock, D Yu, U Sajjan*

**Critical care**

- 33 Effects of mindfulness training programmes delivered by a self-directed mobile app and by telephone compared with an education programme for survivors of critical illness: a pilot randomised clinical trial  
*C E Cox, C L Hough, D M Jones, A Ungar, W Reagan, M D Key, T Gremore, M K Olsen, L Sanders, J M Greeson, L S Porter*
- 43 Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe *E. coli* pneumonia  
*J Park, S Kim, H Lim, A Liu, S Hu, JH Lee, H Zhuo, Q Hao, M A Matthay, J-W Lee*

**Lung cancer**

- 51 Association between age, deprivation and specific comorbid conditions and the receipt of major surgery in patients with non-small cell lung cancer in England: A population-based study  
*A Belot, H Fowler, E N Njagi, M-A Luque-Fernandez, C Maringe, W Magadi, A Exarchakou, M Quaresma, A Turculeit, M D Peake, N Navani, B Racht*

**Lung transplantation**

- 60 Patient outcomes from time of listing for lung transplantation in the UK: are there disease-specific differences?  
*A Kourliouros, R Hogg, J Mehew, M Al-Aloul, M Carby, J L Lordan, R D Thompson, S Tsui, J Parmar*

**Respiratory research**

- 69 Fas activation alters tight junction proteins in acute lung injury  
*R Herrero, L Prados, A Ferruelo, F Puig, R Pandolfi, R Guillamat-Prats, L Moreno, G Matute-Bello, A Artigas, A Esteban, J Á Lorente*

**Brief communications**

- 83 Polysomnography versus limited respiratory monitoring and nurse-led titration to optimise non-invasive ventilation set-up: a pilot randomised clinical trial  
*M Patout, G Arbane, A Cuvelier, J F Muir, N Hart, P B Murphy*

**MORE CONTENTS ►**

**Cover caption:** Therapeutic effect of MSC MVs on lung protein permeability following severe *Escherichia coli* pneumonia in ex vivo perfused human lung. Lung protein permeability at 6 hours as measured by Evan's Blue extravasation. (see Park J, et al., page 48).



This article has been chosen by the Editors to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



- 87** Cystic fibrosis pathogens survive for extended periods within cough-generated droplet nuclei  
*M E Wood, R E Stockwell, G R Johnson, K A Ramsay, L J Sherrard, T J Kidd, J Cheney, E L Ballard, P O'Rourke, N Jabbour, C E Wainwright, L D Knibbs, P D Sly, L Morawska, S C Bell*
- 91** Diabetes mellitus and latent tuberculosis infection: baseline analysis of a large UK cohort  
*C Jackson, J Southern, A Lalvani, F Drobniewski, C J Griffiths, M Lipman, G H Bothamley, J J Deeks, A Imran, O M Kon, S Mpofo, V Nikolayevskyy, M Rees-Roberts, A Sitch, S Sridhar, C-Y Tsou, H Whitworth, I Abubakar*
- 95** Change in biomarkers of type-2 inflammation following severe exacerbations of asthma  
*R Semprini, N Short, S Ebmeier, A Semprini, R Varughese, C T J Holweg, J G Matthews, J Fingleton, M Weatherall, R Beasley, I Braithwaite*
- 
- Chest clinic**  
**Journal club summaries**
- 100** What's hot that the other lot got  
*A C Kidd*